2 results
Approved WMOWill not start
The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease) with an experimental oral study drug named eliglustat in pediatric patients from 2 to 18 years with Gaucher disease.
Approved WMORecruiting
To determine the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D) of RLY-4008 and to determine RLY-4008's safety and tolerability.